Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.
You may also be interested in...
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
Merck Passes Huntington’s RNAi Program To Targeted Genetics
Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.
Amarin To Acquire Ester Neurosciences, Gain Clinical-Stage Neuromuscular Drug
Amarin CEO Stewart tells “The Pink Sheet” DAILY about the company’s partnering strategy for neurology and cardiovascular drugs.